A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption
- 31 October 2009
- journal article
- research article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 61 (4), 614-620
- https://doi.org/10.1016/j.jaad.2009.03.046
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Randomized Double-Blind Trial of Prophylactic Oral Minocycline and Topical Tazarotene for Cetuximab-Associated Acne-Like EruptionJournal of Clinical Oncology, 2007
- Dermatologic side effects associated with the epidermal growth factor receptor inhibitorsJournal of the American Academy of Dermatology, 2006
- Efficacy of Treatment With Tetracyclines to Prevent Acneiform Eruption Secondary to Cetuximab TherapyArchives of Dermatology, 2005
- Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitorsAnnals of Oncology, 2005
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumoursBritish Journal of Dermatology, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Pimecrolimus: A reviewJournal of the European Academy of Dermatology and Venereology, 2003
- Comparison of Epidermal Growth Factor Binding and Receptor Distribution in Normal Human Epidermis and Epidermal AppendagesJournal of Investigative Dermatology, 1984